...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of cardiovascular electrophysiology >Effects of Dronedarone on Clinical Outcomes in Patients with Lone Atrial Fibrillation: Pooled Post Hoc Analysis from the ATHENA/EURIDIS/ADONIS Studies.
【24h】

Effects of Dronedarone on Clinical Outcomes in Patients with Lone Atrial Fibrillation: Pooled Post Hoc Analysis from the ATHENA/EURIDIS/ADONIS Studies.

机译：决奈达隆对单发性心房颤动患者临床疗效的影响：ATHENA / EURIDIS / ADONIS研究的汇总事后分析。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Dronedarone in Lone Atrial Fibrillation. Introduction: Dronedarone has been shown to reduce cardiovascular hospitalizations or death in patients with atrial fibrillation (AF) and additional risk factors. This post hoc exploratory analysis examines its effects in the subgroup of lone AF patients. Methods and Results: Individual data from patients with lone AF enrolled in the EURIDIS, ADONIS, and ATHENA trials were entered in a central database. The effects of dronedarone compared to placebo on the composite endpoint of cardiovascular hospitalizations or death, and their individual components, were evaluated. A total of 432 (192 placebo and 240 dronedarone) patients (7% of the total population) were classified as having lone AF (69.4% male patients, mean age 64 +/- 13 years). The patients were followed for 13.8 +/- 7.2 months. The risk for first cardiovascular hospitalizations or death from any cause in the placebo group after 1 year was 25% in the lone AF group compared to 29% the rest of the population. For patients with lone AF, dronedarone led to a 44% reduction of cardiovascular hospitalizations or death (hazard ratio (HR) 0.56; 95%CI 0.36-0.88, P = 0.004) and to a 46% reduction in cardiovascular hospitalizations alone (HR 0.54; 95%CI 0.34-0.87, P = 0.004) compared to placebo. HR for all-cause mortality was 1.02 (95%CI 0.31-3.34, P = 0.885). All findings were homogeneous across the 3 studies and similar to those observed in the overall population. Conclusion: According to this post hoc analysis, patients with lone AF have a high risk for cardiovascular hospitalization within 1 year. Dronedarone when added to standard of care reduces the risk of cardiovascular hospitalizations in this population. (J Cardiovasc Electrophysiol, Vol. 22, pp. 770-776, July 2011).
机译：决奈达隆在单独房颤中的作用。简介：决奈达隆已被证明可以减少患有心房颤动（AF）和其他危险因素的心血管疾病的住院或死亡。这项事后探索性分析检查了其在孤独性AF患者亚组中的作用。方法和结果：纳入EURIDIS，ADONIS和ATHENA试验的孤独性AF患者的个人数据输入中央数据库。评估了决奈达隆与安慰剂相比对心血管住院或死亡的复合终点及其个体组成的影响。共有432名（192名安慰剂和240名决奈达隆）患者（占总人口的7％）被归为患有孤立性房颤（男性为69.4％，平均年龄为64 +/- 13岁）。随访患者13.8 +/- 7.2个月。单独的AF组在安慰剂组1年后首次因心血管原因住院或因任何原因死亡的风险为25％，而其余人群为29％。对于患有单发性房颤的患者，决奈达隆可使心血管疾病住院或死亡人数减少44％（危险比（HR）0.56; 95％CI 0.36-0.88，P = 0.004），仅心血管疾病住院人数减少46％（HR 0.54） ; 95％CI 0.34-0.87，P = 0.004）。全因死亡率的HR为1.02（95％CI 0.31-3.34，P = 0.885）。在这三项研究中，所有发现均是一致的，与总体人群中观察到的相似。结论：根据这项事后分析，孤立性房颤患者在1年内有较高的心血管住院风险。当将决奈达隆添加到护理标准中时，会降低该人群中心血管疾病住院的风险。 （J Cardiovasc Electrophysiol，Vol.22，pp.770-776，2011年7月）。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号